iBio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IBIO | A89.F | OABI | IMM.L | BMEA | INMB | |
|---|---|---|---|---|---|---|
| Market cap | 51.45M | 63.00M | 755.56M | 20.79M | 44.24M | 41.18M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.3 | — | -19.9 | 0.0 | -0.7 | -3.1 |
| Price/book | 0.5 | -12.5 | 3.0 | 11.1 | 3.7 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −43.06% | −65.78% | +275.36% | −69.00% | −52.92% | −25.42% |
| Today | −2.85% | −0.62% | +0.58% | +2.17% | −1.91% | +0.76% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IBIO news ›Head to Head Comparison: Myriad Genetics (NASDAQ:MYGN) & iBio (NASDAQ:IBIO)
Posted by Michael Walen on Oct 19th, 2026 iBio (NASDAQ:IBIO – Get Free Report) and Myriad Genetics (NASDAQ:MYGN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two…
iBio: Coastlands reports 9.72% passive stake
iBio, Inc. (NASDAQ: IBIO) is a preclinical biotech using AI and computational biology to develop precision antibody therapies for obesity and cardiometabolic disease. - [SCHEDULE 13G] iBio, Inc. Passive Investment Disclosure (>5%) iBio:…
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
October 13, 2026 07:00 ET | Source: iBio, Inc. iBio, Inc. In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start…
iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
TradingView iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
iBio's IBIO-610 with semaglutide preserves muscle better in obesity study, human trials start in 2027
iBio, Inc. announced positive preclinical results from an eight-week obese non-human primate study showing that their antibody drug IBIO-610, combined with semaglutide, preserved muscle mass better than semaglutide alone. The combination…
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody ... iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference SAN DIEGO, Sept.…
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeut... iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as…
iBio Announces Proposed Public Offering
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the ... iBio Announces Proposed Public…
iBio, Inc. Stock 12‑Month Price Target Raised to $5.6, Implies 509% Upside
TradingView iBio, Inc. Stock 12‑Month Price Target Raised to $5.6, Implies 509% Upside - According to estimates from 7 analysts, iBio, Inc. stock's average price target has risen from $5.53 to $5.6, with forecasts ranging fr
iBio initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of iBio (IBIO) with a Buy rating and $7 price target The firm believes IBIO-610’s activin E antibody “looks ... iBio initiated with a Buy at H.C. Wainwright H.C. Wainwright initiated coverage of iBio…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com4
- theglobeandmail.com2
- themarketsdaily.com2
- tradersunion.com2
- tradingview.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.